Guillain-Barré syndrome (GBS) is a rare, immune-mediated neurologic disorder of the peripheral nervous system that is characterized by ascending weakness and paralysis.
1 Between 3000 and 6000 cases of GBS (1-2 cases/100 000 persons) are diagnosed annually in the United States.
2,3 Although the etiology of GBS is unclear, molecular mimicry is thought to play a role in its pathogenesis.
4 Autoimmune antibodies likely target epitopes on peripheral nerves, leading to neuronal demyelination and axonal damage.
4 Production of these autoimmune antibodies may be triggered by an antecedent infection. Approximately two-thirds of patients with GBS report an antecedent gastrointestinal or respiratory infection within 3 weeks before symptom onset.
5 Rarely, vaccination has been associated with GBS. The first epidemiological association was found in 1976, when an increased GBS risk was observed among persons who received the swine flu vaccine.
6 Subsequently, an increased GBS risk was found after recombinant zoster vaccination.
7 Associations between seasonal influenza vaccination and GBS have been inconsistently noted; some studies have shown a small increase in GBS risk among vaccinated persons while others have not.
8,9